

Optimal time of mealtime insulin administration in people with type 1 diabetes

Submission date
15/02/2010

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
25/03/2010

Overall study status
Completed

☐ Statistical analysis plan

☐ Results

Last Edited
25/03/2010

Condition category
Nutritional, Metabolic, Endocrine

☐ Individual participant data

☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Yoeri Matthijs Luijf

Contact details
Academic Medical Centre
Dept of Internal Medicine - Clinical Diabetology
Room F4-252
POBox 22660
Amsterdam
Netherlands
1100DD

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
Optimal Lag Time Study: Optimal timing of rapid-acting insulin analogues administration before meals

Acronym

OLTS

Study objectives

We hypothesize that mealtime insulin administration at 30 or 15 minutes before the start of a meal will result in reduced postprandial glycemic excursions when compared to insulin administration simultaneously with the start of a meal.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Medical Ethical Committee of Academic Medical Centre, Amsterdam approved on the 22nd of January 2009 (ref: MEC 08/349 # 09.17.0121)

Study design

Single-centre randomised open label controlled crossover intervention study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Type 1 diabetes and postprandial glycemic conditions.

Interventions

Ten type 1 diabetics who had been on CSII for at least six months were included in the study. On the day before the first test meal, patients received a subcutaneous CGM sensor (Medtronic CGMS SofSensor) during a visit to the outpatient clinic and were instructed to calibrate the sensor at home according to the manufacturers specifications.

The next day at 08:00 am, patients reported on an empty stomach to the clinical research unit and were admitted. Patients received an intravenous catheter for blood collection. Before the start of the daily study protocol blood glucose was measured by finger prick. If blood glucose was between 3.0 mmol/L and 7.8 mmol/L, the study protocol would commence immediately. If the blood glucose was too high, intravenous insulin aspart was administered. If blood glucose had been corrected to acceptable parameters and if these values remained stable (excursions < 0.6mmol/L) over a period of 1 hour, the study protocol commenced.

Patients were randomized on each study day by means of opaque, sealed envelopes which were sequentially numbered, between insulin bolus administration at three strata; -30, -15 or 0 minutes before the meal. Each patient was provided with a meal that was comparable to their regular morning meal, the meal for one individual patient did not differ over study days. The first hour before the meal blood was sampled every 15 minutes, the first 2 hours after the meal every 10 minutes and the third and fourth hour after the meal every 20 minutes. Blood samples were collected in 2cc sodium fluoride tubes for determination of blood glucose. The insulin bolus was administered by the patients according to their own calculation of carbohydrates in the meal (at this point estimated to be between 4 and 12 IU per meal, depending on the patient and their respective meals).

After the test meal and blood collection, patients would go home continuing to wear the CGM sensor and reported back to the clinical research unit the next day to continue the protocol until all three insulin administration strata had been completed.

After the three study-meals, there is no additional follow-up.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

All outcomes in this study are outcomes derived from the postprandial glucose curve, and as such are a measure of postprandial glucose control on the three study days until 5 hours postprandially.

Key secondary outcome(s)

1. Continuous Glucose Monitoring (CGM) values
2. Number and duration of hypoglycemias
3. Maximum swing of blood-glucose levels
4. Highest blood glucose levels
5. Lowest blood glucose levels
6. Time spent in hyperglycemia

Completion date

30/03/2010

Eligibility

Key inclusion criteria

1. Men or women aged from 18 to 75 years
2. Type 1 diabetes according to the WHO definition
3. Treated with insulin for at least 2 years and by Continuous Subcutaneous Insulin Infusion (CSII) for at least 6 months
4. Body mass index (BMI) < 35 kg/m²
5. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

1. Pregnancy (women of childbearing potential must have an adequate contraception) or breastfeeding
2. Treatment with systemic corticosteroids
3. Treatment with oral antidiabetics within 1 week prior to the first study day
4. Impaired renal function as shown by serum creatinine ≥ 133 $\mu\text{mol/l}$ in men or ≥ 124 $\mu\text{mol/l}$ in women
5. Known impaired hepatic function defined as alanine aminotransferase (ALAT) and / or aspartamine aminotransferase (ASAT) three times greater the upper limit of the normal range
6. Alcohol or drug abuse in the last year
7. Mental condition rendering the patient unable to understand the nature and scope of the study

Date of first enrolment

01/10/2009

Date of final enrolment

30/03/2010

Locations**Countries of recruitment**

Netherlands

Study participating centre**Academic Medical Centre**

Amsterdam

Netherlands

1100DD

Sponsor information**Organisation**

Academic Medical Centre (AMC) (Netherlands)

ROR

<https://ror.org/03t4gr691>

Funder(s)**Funder type**

Hospital/treatment centre

Funder Name

Academic Medical Centre (AMC) (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration